DSM: announces strong growth and increases dividend

Heerlen / NL. (dsm) Royal DSM N.V., the global Life Sciences and Materials Sciences company, reports a solid Q4/2012 with Ebitda of 243 million EUR. Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: «In the context of challenging macro-economic conditions, DSM delivered growth across all clusters in 2012, excluding caprolactam. Nutrition now represents more than 70 percent of total Ebitda and has become a high value, global business with attractive growth prospects across the full value chain». Highlights:

• DSM reports a solid Q4/2012 with Ebitda of 243 million EUR
• Ebitda full year 2012 of 1’109 million EUR with growth in all clusters, except for caprolactam
• Robust performance of Life Sciences driven by Nutrition
• Materials Sciences performed well, except for caprolactam
• Strong cash generation from operating activities of 730 million EUR in 2012
• Dividend increase proposed to 1,50 EUR per ordinary share
• Outlook 2013: moving towards Ebitda of 1,4 billion EUR

Sijbesma: «The significant strategic progress we made during 2012 through our value creating acquisitions and the profit improvement initiatives we have taken leave us well positioned to achieve our long term objectives. In 2013 we will focus on the operational performance and integration of the acquisitions we completed in 2012 with special attention to capturing synergies. We expect strong Ebitda growth in 2013, moving towards 1,4 billion EUR. The Board´s proposal to increase the dividend for the third consecutive year is testament to the stronger DSM we have built in recent years, with more stable growth and profitability going forward».